Preclinical biotechnology company developing in-situ neural regeneration therapies for central nervous system injuries and neurodegenerative diseases
Preclinical biotechnology company developing in-situ neural regeneration therapies for central nervous system injuries and neurodegenerative diseases. Its platform uses delivery vectors to express neural transcription factors and directly convert endogenous astrocytes into functional neurons, aiming to repair neural tissue. Potential applications include stroke, Alzheimer's disease, Parkinson's disease, Huntington's disease, traumatic brain injury, retinal diseases, spinal cord injury, and ALS.